-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HYrosluvVPmb9FAokfAJv4fLI9D/3489T5Fxub5KJ+WS2oYKotwaubRJMvige4nv e3nx4CbKsTDitemLF4IOdA== 0000950130-97-003301.txt : 19970728 0000950130-97-003301.hdr.sgml : 19970728 ACCESSION NUMBER: 0000950130-97-003301 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19970723 ITEM INFORMATION: Other events FILED AS OF DATE: 19970725 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: ROBERTS PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0000853022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222429994 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10432 FILM NUMBER: 97645504 BUSINESS ADDRESS: STREET 1: MERIDIAN CENTRE II STREET 2: 4 INDUSTRIAL WAY W CITY: EATONTOWN STATE: NJ ZIP: 07724 BUSINESS PHONE: 9083891182 MAIL ADDRESS: STREET 1: MERIDIAN CTR II STREET 2: 4 INDUSTRIAL WAY WEST CITY: EATONTOWN STATE: NJ ZIP: 07724 8-K 1 FORM 8-K FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 1997 ROBERTS PHARMACEUTICAL CORPORATION - -------------------------------------------------------------------------------- (exact name of registrant as specified in its charter) New Jersey 1-1-432 22-2429994 - ----------------------- ----------------- ------------------- (State or other (Commission (IRS Employer jurisdiction of File Number) Identification incorporation) Number) Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Address of principal executive offices, including zip code) Registrant's telephone number, including area code: 908-389-1182 Meridian Center II 4 Industrial Way West Eatontown, New Jersey 07724 - -------------------------------------------------------------------------------- (Former name or former address, if changed from last report) - 2 - Item 5. Other Events ------------ Roberts Pharmaceutical Corporation announced today that it has filed with the Food and Drug Administration an Investigational New Drug Application (IND) for LY315535, one of the new gastrointestinal (GI) compounds recently acquired from Lilly. Roberts plans to develop the compound for the treatment of Functional Bowel Disorders (FBD). LY315535 is an orally administrated drug that can act as both a mascarinic receptor antagonist and as a serotonin (5-HT) receptor antagonist with a high degree of selectivity for the 5-HT1A receptor subtype. Because of these two different modes of action on the GI tract, the compound offers the potential to treat a broad spectrum of FBD symptoms with a single drug. It has been estimated that 15% - 20% of the world population has FBD and current therapies such as over-the-counter medicines and prescription antispasmodics tend to provide limited or erratic treatment response. Roberts noted that LY315535 is one of the first new compounds acquired by the Company to be internally advanced towards clinical development, thus an important new phase in Roberts R&D program. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROBERTS PHARMACEUTICAL CORPORATION ---------------------------------- (Registrant) Date: July 25, 1997 By: /s/ Anthony A. Rascio ------------------------------- Anthony A. Rascio Vice President -----END PRIVACY-ENHANCED MESSAGE-----